Skip to main content
. 2023 Jul 22;24(14):11803. doi: 10.3390/ijms241411803

Table 5.

Among solutions to CAR-T limitations which are likely to get to the clinic in the near future, combinations of authorised drugs with CAR-Ts are an important development to curb toxicities.

Cytokine Causing CRS Product Used in Combination
Granulocyte Monocyte Colony Stimulating Factor (GM-CSF) Lenzilumab
Interleukin 1 (IL-1) Anakinra
Proximal TCR Signalling Kinases, (Lck, etc.) Dasatinib